Antibodies to watch in 2025.

MAbs · 2025 · PMC12952251 · PMID 39711140

Europe PMC DOI

hedged sentences

0.1244

closest p · 2.5× alpha

0.5300

boldest claim

The sentences

showed a trendp = 0.1244not close (p > 0.1)

Preliminary data showed a trend toward a survival benefit in the experimental arm with a median OS of 16.07 months, compared to 14.88 months in the control group (HR 0.79, p = 0.1244).

also in 53,322 other papers

did not reach statistical significancep = 0.530not close (p > 0.1)

The median OS results numerically favored datopotamab deruxtecan compared to docetaxel (12.9 versus 11.8 months) but did not reach statistical significance (HR 0.94; 95% confidence interval [CI] 0.78–1.14; p = 0.530).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.